SUPPLIED
University of Auckland research fellow Dr Sarah Gerritsen. The research was part of an international study across 38 countries led by researchers at the University of Antwerp in Belgium. Today, Gerritsen tells
The Detail s Sharon Brettkelly about the surprises in the survey results and why it was no coincidence that people stocked up on junk food at the supermarket, and then rushed to their favourite fast food outlet when lockdown ended. She is already working on a follow-up study looking at the social media accounts of all the large food and drinks companies during the lockdown period, and how they were using the pandemic to promote their products.
Twinkle, twinkle to the grave - The Nation Nigeria News thenationonlineng.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenationonlineng.net Daily Mail and Mail on Sunday newspapers.
Il BDSM è divertente, lo conferma la scienza vanityfair.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vanityfair.it Daily Mail and Mail on Sunday newspapers.
Dec 14, 2020
Researchers answer WHO’s call for tools to stave off poliovirus outbreaks
Researchers found that two novel type 2 oral poliovirus (OPV2) candidate vaccines OPV2-c1 and OPV2-c2 are safe, well-tolerated, and effective in children and infants, as well as adults, and may be an important addition to the existing armamentarium against poliovirus, according to two studies published in
The Lancet.
“Continued emergence and spread of circulating vaccine-derived type 2 polioviruses and vaccine-associated paralytic poliomyelitis from Sabin OPVs has stimulated development of two novel type 2 OPV candidates (OPV2-c1 and OPV2-c2) designed to have similar immunogenicity, improved genetic stability, and less potential to reacquire neurovirulence. We aimed to assess safety and immunogenicity of the two novel OPV candidates compared with a monovalent Sabin OPV in children and infants,” wrote researchers of the first study, led by Xavier Sáez-Llorens, MD, of the Hospital del Ni
A new polio vaccine that could tackle mutated strains of the disease has passed phase II clinical trials, according to two studies published in medical journal The Lancet.